Dapagliflozin for long COVID symptoms
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether a common diabetes drug, dapagliflozin (sold as Farxiga), can help relieve the symptoms of long COVID. If you've had symptoms for months after a COVID infection, this drug might help by improving how your body handles blood sugar and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You tested positive for COVID-19 or were diagnosed with it by a health care provider.
- You have new or ongoing symptoms that started at least 12 weeks after your COVID infection and have lasted at least 8 weeks.
- You do not have diabetes.
- You have not been diagnosed with heart failure.
- You are not taking weight loss medications like liraglutide or semaglutide.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called Apabetalone for people with long COVID. You may be eligible if you have type 2 diabetes, take or are willing to take dapagliflozin, and have had long COVID symptoms for at least 2 months after your COVID infection.
This study tests if the drug dapagliflozin (a medicine that helps protect the heart and kidneys) can improve recovery in patients who needed a breathing machine or blood pressure support in the ICU. If you qualify, you would take the drug after leaving the ICU to see if it lowers the risk of heart or kidney problems.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This trial tests whether dapagliflozin (a diabetes medicine also used for heart protection) can reduce harmful heart “remodeling” after an acute heart attack. It may help your heart function and structure recover over the following 6 months.
This study tests a medication called dapagliflozin, which is usually for type 2 diabetes, to see if it can be used safely in people with type 1 diabetes. It focuses on preventing a serious side effect called ketoacidosis, where the blood becomes too acidic.
This early-phase study tests whether dapagliflozin can improve tiny blood-vessel function in women who have heart-ache-like symptoms but no major blockage on heart scans. If it works, it may help symptoms related to “microvascular” heart circulation problems.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.